Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesCognitive Effects of Second-Generation Antipsychotics: Current Insights into Neurochemical Mechanisms
CNS Drugs, 06/29/09
Fumagalli F et al. - The authors discuss recent preclinical research efforts, including investigation of synaptic mechanisms as well as intracellular signalling pathways and mechanisms involved in neuroplasticity and cell resilience, that may represent new mechanisms participating in the pathogenesis of schizophrenia, particularly at the level of the prefrontal cortex and hippocampus, and that might lead to the development of drugs that can counteract, at least partially, the cognitive impairments typical of schizophrenia.
Related Articles
Auditory gating deficit to human voices in schizophrenia: A MEG study
Schizophrenia Research, 10/01/09
Relevance Score: 93%
Age at onset and cognition in schizophrenia: meta-analysis
British Journal of Psychiatry, 10/06/09
Relevance Score: 92%
Beyond symptom dimensions: Schizophrenia risk factors for patient groups derived by latent class analysis
Schizophrenia Research, 10/30/09
Relevance Score: 91%
Functional Magnetic Resonance Imaging of Inner Speech in Schizophrenia
Biological Psychiatry, 10/26/09
Relevance Score: 91%
Sensory Processing in Schizophrenia: Neither Simple nor Intact
Schizophrenia Bulletin, 10/19/09
Relevance Score: 91%
Today in Neuro/Psych pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Propylene Glycol Accumulation in Critically Ill Patients Receiving Continuous Intravenous Lorazepam Infusions
Annals of Pharmacotherapy, 11/25/09
Effect of cilnidipine vs losartan on cerebral blood flow in hypertensive patients with a history of ischemic stroke: a randomized controlled trial
Acta Neurologica Scandinavica, 11/25/09
A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimers disease: a post hoc analysis
Current Medical Research and Opinion, 11/25/09
Sponsor
Article Search
Sponsor